Cholesteryl Cyclodextrin for Enhanced Delivery of Doxorubicin and 5-Fluorouracil
This study (1) aims to build on previously published results that characterized cholesteryl-modified β-cyclodextrin (CD21chol) as a carrier for 5-fluorouracil. (2)
A forum for researchers, students and applicants in the field of cyclodextrin technology
This study (1) aims to build on previously published results that characterized cholesteryl-modified β-cyclodextrin (CD21chol) as a carrier for 5-fluorouracil. (2)
In this study, nanogels were developed using thiolated hyaluronic acid (HASH) and vinyl sulfonated β-cyclodextrin (CDVS) via a water-in-oil emulsion
Combination therapy has emerged as a promising strategy in cancer treatment, aiming to enhance therapeutic efficacy and overcome drug resistance.
A supramolecular system was developed for codelivery of doxorubicin (Dox) and p53 gene based on a β-CD-containing star-shaped cationic polymer.
In the past few years, drug delivery systems have been used extensively to improve solubility, stability, and pharmacokinetics of chemotherapeutic
Water-soluble C60-β-cyclodextrin conjugates were prepared to encapsulate and deliver doxorubicin to the cell nucleus. The behaviour of the fullerene aggregates
The aim of this study was to evaluate the interaction between catanionic vesicles based on amphiphilic cyclodextrins (ModCBHD) and DNA–Doxorubicin
In the last decade, nanotechnological progress has generated new opportunities to improve the safety and efficacy of conventional anticancer therapies.
D-maltose-clicked derivative of β-cyclodextrin (β-CD-M) was synthesized to compare and investigate its capability as an anticancer drug nanocarrier [1]. The
Nanosized metal-organic frameworks (nanoMOFs) MIL-100(Fe) are highly porous and biodegradable materials that have emerged as promising drug nanocarriers. A challenging